Leerink Partnrs Predicts Tourmaline Bio FY2029 Earnings

Tourmaline Bio, Inc. (NASDAQ:TRML) – Research analysts at Leerink Partnrs issued their FY2029 earnings estimates for Tourmaline Bio in a research report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith expects that the company will post earnings per share of ($3.15) for the year. The consensus estimate for Tourmaline Bio’s current full-year earnings is ($2.99) per share.

A number of other brokerages have also commented on TRML. HC Wainwright restated a “buy” rating and issued a $49.00 target price on shares of Tourmaline Bio in a research note on Wednesday, December 11th. Cantor Fitzgerald reiterated an “overweight” rating and set a $25.00 target price on shares of Tourmaline Bio in a research report on Wednesday, December 11th. BMO Capital Markets initiated coverage on shares of Tourmaline Bio in a research note on Friday, December 6th. They set an “outperform” rating and a $50.00 price target for the company. Finally, Guggenheim reissued a “buy” rating on shares of Tourmaline Bio in a report on Wednesday, December 11th. Six analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and a consensus price target of $54.00.

Tourmaline Bio Stock Down 6.2 %

Shares of TRML opened at $14.99 on Friday. Tourmaline Bio has a 52 week low of $12.12 and a 52 week high of $48.31. The company has a 50-day simple moving average of $20.24 and a 200-day simple moving average of $21.09.

Tourmaline Bio (NASDAQ:TRML) last posted its quarterly earnings results on Thursday, November 7th. The company reported ($0.78) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.84) by $0.06.

Institutional Trading of Tourmaline Bio

Large investors have recently made changes to their positions in the business. Brooklyn Investment Group acquired a new position in Tourmaline Bio during the 4th quarter worth about $32,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Tourmaline Bio by 63.7% during the third quarter. China Universal Asset Management Co. Ltd. now owns 4,932 shares of the company’s stock worth $127,000 after purchasing an additional 1,920 shares in the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Tourmaline Bio during the third quarter valued at approximately $226,000. Quest Partners LLC increased its holdings in shares of Tourmaline Bio by 145.4% in the third quarter. Quest Partners LLC now owns 9,381 shares of the company’s stock valued at $241,000 after purchasing an additional 5,559 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new position in Tourmaline Bio in the 3rd quarter worth approximately $357,000. Institutional investors own 91.89% of the company’s stock.

Tourmaline Bio Company Profile

Tourmaline Bio, Inc operates as a clinical biotechnology company that develops medicines for patients with life-altering immune and inflammatory diseases. It develops TOUR006, a human anti-IL-6 monoclonal antibody that selectively binds to interleukin-6, a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders.